Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
about
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@en
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@nl
type
label
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@en
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@nl
prefLabel
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@en
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@nl
P2093
P2860
P1476
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
@en
P2093
Bradley J Monk
Ira Jacobs
Julie Ann Rosenberg
Warner K Huh
P2860
P2888
P356
10.1186/S40661-017-0045-X
P577
2017-03-21T00:00:00Z
P6179
1084253138